

Index

A

Activated PI3K syndrome (APDS), 289–290, 292, 297
ADPS1, 289–290, 292
ADPS2, 289–290, 292
AGRP, 275
AI. *See* Artificial intelligence
AIF, 53
AKT
 cancer role, 123, 193
 endomembranes, 146–147
 history of study, 4, 6–7
 immune function, 285
 isoforms and functions, 31–32
 PTEN variant effects, 71, 73–74
 structure, 30–31
 substrates, 31–32
AMPK, 194, 276
AP-2, 145
APC, 54, 117
APC/C, 41, 92
APDS. *See* Activated PI3K syndrome
Apoptosis, PTEN mechanisms, 26
APPL1, 147, 149
ARHGAP21, 60
Artificial intelligence (AI), systems pathology
 approaches, 313–314
ASD. *See* Autism spectrum disorder
ASHP-1, 52
ATM, 4, 51, 89–90, 92, 135
Autism spectrum disorder (ASD)
 genetic studies, 215
 long-term potentiation/depression studies,
 255–257
 neuritogenesis and arborization, 253, 255
 neuronal stem cell/precursor cell studies
 hypertrophy, 252–253
 migration and lamination, 251–252
 proliferation and differentiation, 249–251
 nuclear function of PTEN, 93, 95
 overview, 213–215, 227–228, 247
 PTEN-ASD
 brain pathology, 216–218
 clinical guidelines, 220–221
 cross-level model, 219
 mouse models
 acoustic startle, 240
 aggression, 237
 anxiety, 238

 aversive learning and memory tasks, 239
 balance, 240–241
 behavioral phenotypes by mutation,
 231–234
 depression, 238
 fine motor skills, 241
 intellectual disability, 238–239
 locomotion, 240
 motor learning, 240–241
 nest building, 237
 prepulse inhibition, 240
 prospects for study, 241–242
 repetitive behavior, 237–238
 seizure, 241
 sensory function, 240
 sex differences, 236
 sleep and circadian rhythms, 239–240
 social interest, 228, 235
 social recognition, 235
 types, 229–230, 248–249
 ultrasonic vocalization, 237
 mutations, 170–171, 175, 215
 neurobehavioral findings, 216
 neuropsychiatric spectrum, 218, 220
 prospects for study, 221–222
 myelination studies, 257–258
AZD6482, 313

B

Bannayan–Riley–Ruvalcaba syndrome (BRRS),
 106–107, 166, 283, 308
BCAP, 284
B cell, PTEN
 deletion studies, 187
 function, 288–289
 lineage commitment, 189
B-cell receptor, 284, 295
Bcl2, 160
BDNF, 250
 β -Arrestin, 56–57, 60
 β -Catenin, 191, 194, 250
Bioluminescence resonance energy transfer (BRET),
 PTEN conformation studies, 60–63
BMI1, 54, 58, 121
Braf, 160
BRAF, 173
Brain tumor. *See also* Glioblastoma

Index

Brain tumor (*Continued*)

PTEN mutations, 173–174

PTEN therapeutic targeting, 175–176

BRCA1, 90–91

BRCA2, 90

Breast cancer, PTEN

immunohistochemistry, 329–330

loss, 324

mutations, 172, 311

BRET. *See* Bioluminescence resonance energy transfer

BRRS. *See* Bannayan–Riley–Ruvalcaba syndrome

C

CAE-T, 194

CAF. *See* Cancer-associated fibroblast

CAL-130, 193

Cancer. *See specific cancers*; Tumor microenvironment

Cancer-associated fibroblast (CAF), PTEN in stroma, 202–203

CASC2, 105

CBP, 53, 250

CD19, 189, 284

CD28, 284

Cdc42, 60

Cdkn1b, 119–120

CDKN2, 5

Cell-free DNA (cfDNA), liquid biopsy, 311

CENP-A, 90

CENP-B, 90

CENP-C, 90, 131, 158

cfDNA. *See* Cell-free DNA

CFTR, 55, 60

Chk1, 134

CHK2, 90

Chromatin remodeling

assembly, 156–157

H1 role in gene expression and chromatin dynamics, 157–158

PTEN functions

chromatin condensation, 130–131, 159–160

DNA replication and repair, 158–159

glioblastoma oncogenesis, 160

heterochromatin structure maintenance, 160

overview, 158

prospects for study, 160–162

CNOT6L, 105

Cowden syndrome, 5, 106–107, 165–166, 168, 283, 308–309

CPBP, 106

CPE, 271

CREB, 33, 250–251

CTBP2, 106

CTNNA1, 189

Cyclin D1, 92

D

DAXX, 89, 92, 160

DC. *See* Dendritic cell

Dendritic cell (DC), PTEN function, 289

Diabetes. *See* Insulin resistance

DJ1, 53–54, 58, 274–275

DKK1, 105

DLG1, 54, 57

DNA repair, PTEN function, 158–159

Drebrin, 28

E

E1A, 3

E2F-1, 130

EBPA, 189

EEA1, 149

EG5, 133–136

EGF, 207

EGFR, 149, 323

Elf1, 162

ELISA. *See* Enzyme-linked immunosorbent assay

Endocytosis

AKT and endomembranes, 146–147

endosomes as signaling platforms, 147–149

evolution of PTEN function, 149

overview, 141–143

phosphatidylinositols and organelle identity control, 144

PI(3)P production, 144–145

PIP₃ studies, 145–146

prospects for study, 149

PTEN recruitment to endosomes, 143–144

Endometrial cancer, PTEN

immunohistochemistry, 328

loss, 324

mutations, 173, 310

Endothelial cell, PTEN in stroma, 203

Enzyme-linked immunosorbent assay (ELISA), PTEN in cancer, 327, 331

ERG, 121

ERK, 275

ERR, 33

ETS2, 206–207

F

FAK, 26, 72–74, 194, 275

FERIL4, 105

FGF8b, 121

FGF21, 273

FGFR2, 51

FGFR3, 51

53BP1, 54, 90–91

FKBP, 144

4E-BP1, 286

FOXA2, 272
FOXO, 186, 189, 285, 288
FOXO-1, 272–275
FoxP3, 203–204

G

Gas5, 105
GEMM. *See* Genetically engineered mouse models, PTEN
Genetically engineered mouse models, PTEN autism
models. *See* Autism spectrum disorder
cancer-associated mutations, 122–123
down-regulation
 combination with tumor suppressor loss or
 oncogene gain, 119–122
 hypomorphic model, 117–118
 tissue-specific deletion
 hepatocyte, 119
 mammary gland, 119
 prostate, 118–119
 T cell, 119
 whole-body manipulation, 116–117
elevation of expression and function, 122
overview, 115–116
prospects, 123
Genome maintenance, PTEN
 checkpoint control, 134–135
 chromatin compaction, 130–131
 chromatin remodeling. *See* Chromatin remodeling
 chromosome integrity, 131–132
 chromosome segregation, 132–134
 fibroblast, PTEN maintenance of stem cell niche and
 genomic stability, 207–208
 genome duplication, 134
 nuclear PTEN and genomic stability maintenance,
 90–92
 overview, 127–130
 prospects for study, 135–136
GLI2, 208
Glioblastoma, PTEN
 immunohistochemistry, 328
 loss, 324
 mutations, 310–311
 role in oncogenesis, 173
GLUT4, 273
GSK3, 51, 205, 285–286
GSK-3 β , 147, 250, 253, 257, 270, 272–273

H

H1, 157–160
H2A, 157
H2AX, 90–91
H3, 157
H3.3, 160
HAUSP, 88

HDAC, 131
HDAC6, 53
Hematopoiesis
 overview
 PTEN functions
 deletion studies, 187
 lineage commitment
 B cell, 189
 myeloid lineage, 189–190
 T cell, 188–189
 stem cell renewal, 186, 188
HER2, 121, 323
HES1, 250
HIAT1, 106
HIF1A, 106, 171, 286
HKII, 32
Homologous recombination, 90
HOTAIR, 105
HP1 α , 92, 131, 160
HRS, 143

I

ICOS, 284
IGF-1, 257
IGF2BP1, 106
IHC. *See* Immunohistochemistry
IL-6, 275
IL-7, 188
Immune thrombocytopenia (ITP), 292
Immunodeficiency, PHTS, 290
Immunohistochemistry (IHC), PTEN in cancer, 325–331
Infection, PTEN in immune response, 292, 295
Insulin resistance, PTEN studies
 adipose tissue, 274–275
 brain, 275
 clinical implications, 267
 insulin signaling pathway, 265–267
 islet cells, 267, 270
 knockout mice and metabolic phenotypes, 268–269
 liver, 272–273
 prospects, 276
 skeletal muscle, 273–274
 thyroid, 275–276
IPO11, 59
IRS1, 175
ITP. *See* Immune thrombocytopenia

J

JAGGED-1, 207

K

KLF6, 106
Kras, 160
KRAS, 2

Index

L

LDD. *See* Lhermitte–Duclos disease

Leukemia

AML, 190

B-ALL, 190

cancer stem cells, 191, 193–194

PTEN

deletion and mutation, 190–191

knockout mouse models, 191

prospects for study, 194–195

therapeutic targeting, 193–194

T-ALL, 188–194

Lhermitte–Duclos disease (LDD), 308

Linc-USP16, 105

Lipogenesis, PTEN regulation, 33

Lung cancer, PTEN

immunohistochemistry, 329

loss, 324

role, 174

Lymphoma

DLBCL, 190

PTEN

deletion and mutation, 190–191

knockout mouse models, 191

prospects for study, 194–195

therapeutic targeting, 193–194

M

Macrophage, PTEN

function, 289

stroma, 203

MAGI-1, 54, 57

MAGI-2, 51, 57

MAGI-3, 51, 54

MAM, 250

MAN2C1, 54, 58

MAST1, 54, 58

MAST2, 54, 58

MAST3, 54, 58

MC1R, 54, 56

MCM2, 26, 92, 134, 159

MDC1, 92

Melanoma, PTEN mutations, 173

METTL14, 108

METTL3, 108

MG-132, 175

MicroRNA

insulin secretion regulation, 271

PTEN regulation, 100–104

PTEN regulation in tumor microenvironment, 205

PTEN/Ets2/miR30 axis regulation of oncogenic secretome, 206–207

MME, 55

Mouse models. *See* Genetically engineered mouse models, PTEN

MPD. *See* Myeloproliferative disorder

mRNA regulation, *PTEN*

adenosine methylation, 108

competing endogenous RNA, 103, 105–106

microRNA, 100–104

overview, 99–100, 108

polyadenylation variants, 107–108

RNA-binding proteins, 106

splice variants, 106–107

mTOR, 4, 31, 188

mTORC1, 147, 188, 253, 255, 257, 270–274, 285

mTORC2, 31, 146, 175, 188, 255

MVP, 59, 88, 155

MYC, 121–122, 194

Myelination, PTEN-ASD studies, 257–258

Myeloproliferative disorder (MPD), 189

MYO5A, 56

N

NAFLD. *See* Nonalcoholic fatty liver disease

Natural killer cell, PTEN function, 289

Ndfip1, 93

NDGR2, 51

NEAT1, 105

NEDD-4, 255

Nedd4, 93

NEDD4-1, 52–53, 78, 88, 205

NEB, 60

Neutrophil, PTEN function, 289

Nfkb2, 160

NHERF1, 54

Nitric oxide synthase (NOS), 53

Nkx3.1, 120–121

NMDAR, 256

Nonalcoholic fatty liver disease (NAFLD), 33

NOS. *See* Nitric oxide synthase

NOTCH, 121

NOTCH1, 193–194

NOTCH3, 207

NRAS, 106

NSD2, 54, 92

Nuclear PTEN

Cell-cycle control, 92

detection, 87–88

diseases, 93–94

functions, 89–90

genomic stability maintenance, 90–92

localization mechanisms, 88–89

prospects for study, 95

O

Oncogene concept, historical perspective, 1–2

ORLN1, 105

OSBP, 144

- OTUD3, 52
- Ovarian cancer, PTEN
 - immunohistochemistry, 330
 - loss, 324
- P**
- p53, 3, 41, 128, 130, 168, 273
- p300, 350
- Pancreatic cancer, PTEN studies, 174, 330–331
- PAR-3, 54, 58
- PARK7, 58
- PARP, 175, 323, 325
- PCAF, 53
- PCNA, 134
- PD-1, 175–176
- PDGF, 4
- PDK1, 146
- PDX-1, 271
- PEPCK, 273, 275
- PGC-1 α , 274
- PHLPP1, 295
- Phosphatidylinositols. *See also* Endocytosis
 - insulin signaling pathway, 265–267
 - organelle identity control, 144
 - PTEN dephosphorylation, 30
 - types and cell compartmentalization roles, 142
- PHTS. *See* PTEN hamartoma tumor syndromes
- PI3K
 - discovery, 2
 - immune function, 283–284
 - isozymes, 4
 - pathway activation in cancer, 3–4, 6
 - PI3K β , 313
 - PI3K γ , 297
 - signaling regulation, 31
- PIAS α , 52
- PIK3R1, 56
- PLK1, 51
- PNUTS, 54, 59
- POM, 275
- Posttranslational modifications, PTEN
 - acetylation, 49, 53
 - gene variants, 75–78
 - methylation, 50, 53–54
 - nitrosylation, 50, 53
 - overview, 11, 16–17, 42–43, 334
 - oxidation, 50, 53
 - phosphorylation, 43–46, 51–52
 - ribosylation, 50, 53–54
 - SUMOylation, 46–49, 52–53
 - ubiquitylation, 46–49, 52
- PP2A, 51
- PPAR- γ , 272, 274
- Prdx1, 53
- PREX2, 54, 59, 73
- Prostate cancer, PTEN
 - immunohistochemistry, 328
 - loss, 324
 - mutations, 174, 311
- Proteus syndrome, 166, 174, 308
- PTBP1, 106, 168
- PTEN
 - dimerization, 18
 - dual phosphatase activity, 23–25, 41
 - family members, 158
 - functional overview, 70, 247–248, 306
 - gene cloning, 5–6
 - genome maintenance. *See* Chromatin remodeling; Genome maintenance, PTEN
 - history of study, 5–7, 11
 - immunodetection in cancer
 - antibody reactivity, 333–336
 - enzyme-linked immunosorbent assay, 327, 331
 - expression in tumors, 322–325
 - immunohistochemistry, 325–331
 - isoforms, 332
 - overview, 322
 - prospects, 336–337
 - reverse phase protein array, 331
 - interacting proteins, 54–60
 - lipogenesis role, 33
 - membrane interactions, 16–17
 - metabolism regulation, 32–33
 - mouse models. *See* Genetically engineered mouse models, PTEN
 - mRNA regulation. *See* mRNA regulation, *PTEN*
 - nuclear. *See* Nuclear PTEN
 - oligomerization, 55
 - posttranslational modifications. *See* Posttranslational modifications, PTEN structure
 - C2 domain, 14–15
 - carboxy-terminal domain, 15–16
 - overview, 12–13, 23–24, 28, 40–41, 306
 - phosphatase domain, 13–14
 - PIP₂-binding motif, 13
 - prospects for study, 18–19
 - substrates
 - lipids, 29–32
 - proteins, 25–28
 - translational variants, 11, 17–18
- PTEN-ASD. *See* Autism spectrum disorder
- PTEN hamartoma tumor syndromes (PHTS)
 - artificial intelligence in systems pathology approaches, 313–314
 - cancer type risks, 168
 - diagnostic criteria, 308–309
 - genetic testing
 - liquid biopsy, 311

Index

- PTEN hamartoma tumor syndromes (PHTS) (*Continued*)
 pseudogene and isoforms, 309–310
 sporadic tumors, 310–312
 techniques, 309
genotype–phenotype correlations,
 79, 171, 308
immune phenotype, 290, 292
mouse models, 115
mutation spectrum, 166, 168–172, 174, 307
overview, 39, 69, 247, 308
prospects for study, 176
therapeutic targeting, 174–175, 311, 313
PTEN-L, 17–19, 41, 158, 253, 310, 332, 335
PTEN-M, 310, 332
PTEN-N, 310, 332
PTEN-O, 310, 332
PTENP1, 103, 105, 205, 309–310
PTEN variants
 clinical significance, 79–82
 enzyme function, 71–73
 genetic testing. *See* PTEN hamartoma tumor syndromes
 genotype–phenotype correlations in PTEN hamartoma tumor syndromes, 169–172, 308
 high-throughput mutagenesis studies, 78–79
 overview, 69–71
 posttranslational modifications, 75–78, 334
 prospects for study, 82
 sporadic cancers, 172–174
 subcellular localization, 73–75
PTK6, 27–28, 72–74
- R**
RAB5, 143, 147, 149
Rab7, PTEN dephosphorylation, 26
Rad51, 52, 134, 159, 174, 207
RAG, 188, 193
Rak, 54
RAN, 155
Ran, 88
RB1, 3, 105–106
RB1, 3–5
RBM38, 106
RBPJ, 250
Reverse phase protein array (RPPA),
 PTEN in cancer, 331
RFP, 52
RIP2, 270
RNAPII, 162
RNF146, 52
RNF5, 205, 208
ROCK, 51, 60
RPA1, 73, 134, 158
RPPA. *See* Reverse phase protein array
- S**
S1PR2, 55, 60, 62
SARA, 147
SCAP, 33
SDHB, 171
SDHC, 171
SDHD, 171
SERINC1, 105
SHIP1, 295
SHIP2, 146
SHP1/2, 295
SIPL1, 54
SIRT1, 53
SLC9A3R1, 58
SMAD2, 147
SMAD4, 5
SMYD2, 53
SOX9, 121
SPI1, 193
Spt4/5, 162
SREBP, 33
SREBP-1c, 273–274
STAT3, 275
SUMO-1, 89
SV40, early studies, 2–3
- T**
T cell, PTEN
 deletion studies, 187
 function, 286–288
 lineage commitment, 188–189
 stroma, 203–204
T-cell receptor, 284, 286
TGF- α , 208
Thyroid cancer, PTEN mutations, 172–173
TME. *See* Tumor microenvironment
TNKS1, 54
TNKS2, 106
TNKS2, 54
TNRC6B, 106
TOP2A, 92
TP53, 106, 121
TPIP, 336
TPTE, 336
Triciribine, 193
Trp53, 121
TSC1, 270
Tsc2, 120
TSC2, 147, 270, 285
Tumor microenvironment (TME)
 fibroblast PTEN
 extracellular matrix modulation, 208
 maintenance of stem cell niche and genomic stability, 207–208
 immunological role of PTEN, 295

- overview, 201–202
- prospects for PTEN studies, 208–209
- PTEN/Ets2/miR30 axis regulation of
 - oncogenic secretome, 206–207
- PTEN regulation
 - epigenetic, 204–205
 - genetic, 204
 - protein stability, 205
- stromal cell compartment PTEN
 - cancer-associated fibroblast, 202–203
 - endothelial cell, 203
 - macrophage, 203
 - T cell, 203–204
- T**
- Tumor suppressor concept, historical perspective, 2–3
- TXNIP, 53
- U**
- UCP-1, 274
- USP10, 52
- USP11, 52
- USP13, 52
- USP7, 52
- V**
- VAPA, 105
- VCAN, 105
- VEGF-A, 203
- W**
- WWP1, 52, 63, 116, 122, 297
- WWP2, 52, 54, 205
- X**
- XIAP, 52, 88, 205
- Z**
- ZEB2, 105